Annual report pursuant to Section 13 and 15(d)

Mergers and Acquisitions (Additional Information) (Details)

v3.23.1
Mergers and Acquisitions (Additional Information) (Details) - USD ($)
Dec. 31, 2022
Dec. 28, 2022
Jan. 01, 2022
Business Acquisition [Line Items]      
Preferred stock, shares authorized (in shares) 2,000,000   2,000,000
Convertible preferred stock, par value $ 0.001   $ 0.001
Deferred Tax Liabilities $ 195,000   $ 0
Estimated useful life of intangible assets 10 years    
Series S [Member]      
Business Acquisition [Line Items]      
Fair Value of Stock Issued   $ 14,500,000  
Deferred Tax Liabilities   4,800,000  
Intangible Assets   $ 19,300,000  
Estimated useful life of intangible assets   10 years  
Soin Therapeutics LLC [Member]      
Business Acquisition [Line Items]      
Business combination, description   Dr. Soin may convert up to three million dollars of value of the Series S Stock into shares of the Company's common stock commencing one year from the closing and may convert up to an additional $10 million of value of the Series S Stock into shares of the Company's common stock from and after the sooner of (y) the issuance by the FDA of New Drug Approval for low-dose naltrexone for treating pain or (z) 10 years from the closing. Further, during the 10-year period following the closing, Dr. Soin may convert up to an additional $17 million of value at a rate of five percent of the gross revenues that the Company receives in connection with sales or license revenue from the product.  
Soin Therapeutics LLC [Member] | Series S [Member] | Stock Conversion 1 [Member]      
Business Acquisition [Line Items]      
Conversion of stock, amount converted   $ 3,000,000  
Soin Therapeutics LLC [Member] | Series S [Member] | Stock Conversion 2 [Member]      
Business Acquisition [Line Items]      
Conversion of stock, amount converted   10,000,000  
Soin Therapeutics LLC [Member] | Series S [Member] | Stock Conversion 3 [Member]      
Business Acquisition [Line Items]      
Conversion of stock, amount converted   $ 17,000,000  
Soin Therapeutics LLC [Member] | STI Merger Sub, Inc. [Member]      
Business Acquisition [Line Items]      
Common stock, shares outstanding, percentage   4.99%  
Soin Therapeutics LLC [Member] | STI Merger Sub, Inc. [Member] | Series S [Member]      
Business Acquisition [Line Items]      
Preferred stock, shares authorized (in shares)   200,000  
Convertible preferred stock, par value   $ 300.00  
Stock issued during period, shares, acquisition   100,000  
Stock issued during period, value, acquisition   $ 13,000,000  
Stock issued during period, additional value, acquisitions   17,000,000  
Busienss acquisition, shares issued, fair value   $ 30,000,000